Table 1 Baseline characteristics of patients
Variable | Total (n = 122) |
|---|---|
Female, n (%) | 99 (81.1) |
Age, years | 56.9 ± 16.3 (59.0) |
Weight, kg | 53.8 ± 10.5 (52.0) |
Disease duration, years | 8.2 ± 9.4 (4.0) |
DAS28-ESR | 4.48 ± 1.24 (4.29) |
Tender joint count | 3.6 ± 4.7 (2) |
Swollen joint count | 5.2 ± 4.3 (4) |
Physician’s VAS | 35.5 ± 21.3 (30) |
Patient’s VAS | 40.2 ± 25.3 (36.5) |
ESR, mm/h | 47.2 ± 35.6 (41) |
CRP, mg/dL | 1.55 ± 2.14 (0.53) |
RF-positive, n (%) | 84 (68.9) |
ACPA-positive, n (%) | 77 (73.3) |
Stage I/II/III/IV, % | 25.4/37.3/2.5/34.7 |
HAQ-DI | 0.95 ± 0.80 (0.75) |
MTX use, n (%) | 101 (82.8) |
MTX dose, mg/week | 9.8 ± 3.1 (10.0) |
Oral steroid use, n (%) | 36 (29.5) |
Oral steroid dose, mg/day | 5.0 ± 2.8 (5.0) |
Prior use of biologics, n (%) | 35 (28.7) |